Loading
companiesCompany
Shanghai Pharmaceuticals
Shanghai Pharmaceuticals is one of China's largest drug makers and distributors; its research arm is developing SPH4336, an oral CDK4/6 inhibitor for breast cancer.
Also called: Shanghai Pharmaceuticals HoldingSPH上海医药HKEX:2607SSE:601607
Overview
Shanghai Pharmaceuticals Holding, listed in Shanghai and Hong Kong, manufactures generic and innovative medicines and runs one of China's biggest pharmaceutical distribution networks. Its oncology research includes SPH4336, a selective CDK4/6 inhibitor in phase 1/2 trials with endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer, and the PD-L1 and TIGIT programmes of its biologics subsidiaries.
Headquarters
Shanghai, CN
Scorecard
All companies#383of 1244 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Large pharma · HKEX:2607
Stage
Public
Website
Phase 3small molecule
SPH4336 is an experimental small-molecule drug from Shanghai Pharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
drugs
Phase 3small molecule